Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
about
Prognostic Significance of Hypoxia-Inducible Factor Expression in Renal Cell Carcinoma: A PRISMA-compliant Systematic Review and Meta-AnalysisActive angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy.VHL, the story of a tumour suppressor gene.Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.In vivo evaluation of battery-operated light-emitting diode-based photodynamic therapy efficacy using tumor volume and biomarker expression as endpoints.Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomyPrognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.Deep sequencing reveals microRNAs predictive of antiangiogenic drug responsePrognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Pharmacogenomic biomarkers for personalized cancer treatment.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma.A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.Precision medicine from the renal cancer genome.Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review.Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.Change in platelet count as a prognostic indicator for response to primary tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma.Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.The HIF and other quandaries in VHL disease.Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis.
P2860
Q26781470-6E687271-8E5E-418D-9C7E-C956406019CEQ33682981-3C2823EF-757A-4543-9DEB-78ED9B2A06BCQ34455226-0F04A994-87A7-4944-BFED-BF260C9C18BDQ35451764-ED748FD7-0096-4E43-9E51-FBD571F8546BQ35534013-6CE27DD8-4E47-4A50-9CD3-D6EE1EB06AA4Q35540063-55E1F890-A83C-4433-9540-442E442E7734Q36326385-ABE65EC1-8DDC-48FA-84BC-B03AF36B7CEFQ36893510-C196B9D4-A2DF-4126-84D7-1E1843B6DCB8Q37151272-95E29252-0474-4A5F-A191-35FB340547EBQ37277227-B99C2CCF-C611-450B-8B87-D2F289A611BBQ38196855-FA97F3D8-8461-4A98-957E-F1E6F1EFB393Q38262008-C72622C6-B4D5-4F64-9818-0D97D2D3AD1FQ38334611-DB77B272-4940-46C1-8E8C-CBAEAA9FDF05Q38402997-E3DC9044-0E5F-49DD-B0C1-5AC4F472E8D4Q38431622-E72A8276-6AFD-4362-A898-792DAC92244EQ38720430-BF03A460-6A9C-40CF-987C-4190F41DC086Q38768663-3CCDD816-6897-455E-96BE-15E08B24C66EQ38970282-B4B0FC21-5002-4563-8D8B-5DDE5C646F9DQ39095254-2F29433F-6AE0-46FB-857D-919F550E92D4Q40177329-3FF8E17F-098A-4D41-8CA2-89A327EEED96Q40836247-2FE0AF60-0116-460B-B450-42F0584DC80AQ42364455-87B2B603-1B07-4A40-AC48-C6FFBDD3EC61Q45945323-5E1B7CF8-77CD-4D80-96B5-421FF55114FFQ46485254-80B9FEA9-AD46-45D5-B5F2-FA280C8F24E5Q50026055-7916DC37-BB3E-4405-9604-27ABFEFD66EAQ51652607-53B91786-46BC-4A03-86B1-C2B9D56A888AQ52582783-3E593E0B-D427-4567-90C1-2716F8CDB9C1Q52821559-B62A7A0D-9EB0-44D6-B4CB-12E75F25FD83Q54977082-F2893984-80DF-45CB-9DC3-577B08E39DC4Q55265947-683531FC-FDE3-47E0-8DB7-D7B733B00EE6
P2860
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prospective study assessing hy ...... ear-cell renal cell carcinoma.
@en
Prospective study assessing hy ...... ear-cell renal cell carcinoma.
@nl
type
label
Prospective study assessing hy ...... ear-cell renal cell carcinoma.
@en
Prospective study assessing hy ...... ear-cell renal cell carcinoma.
@nl
prefLabel
Prospective study assessing hy ...... ear-cell renal cell carcinoma.
@en
Prospective study assessing hy ...... ear-cell renal cell carcinoma.
@nl
P2093
P50
P356
P1433
P1476
Prospective study assessing hy ...... lear-cell renal cell carcinoma
@en
P2093
A González Del Alba
D E Castellano
J A Arranz
J Bellmunt
M A Climent
P304
P356
10.1093/ANNONC/MDT219
P50
P577
2013-06-20T00:00:00Z